期刊文献+

狼疮性肾炎患者血清和肾内B淋巴细胞刺激因子及BR3的表达 被引量:3

Serum and intrarenal expression of B lymphocyte stimulator and BR3 in lupus nephritis patients
下载PDF
导出
摘要 目的探讨B淋巴细胞刺激因子(BlyS)及其Blys受体3(BR3)在狼疮性肾炎(LN)中的作用。方法 ELISA法检测系统性红斑狼疮(SLE)患者及正常健康体检者血清BlyS、肿瘤坏死因子-α(TNF-α)和白介素-1(IL-1)的表达水平,免疫组化法检测肾活检确诊为LN的患者及正常对照者肾组织中BlyS及其BR3的表达水平。结果 SLE患者血清Blys、TNF-α以及IL-1的水平显著高于正常对照者(P<0.01);正常对照者的肾小管上皮细胞可中等强度表达BlyS,而LN患者除了肾小管上皮细胞外,肾小管间质浸润的炎性细胞也可表达Blys;正常对照肾组织内无BR3的表达,而LN患者肾组织内有极少BR3的表达,仅见于炎性细胞聚集区;LN患者肾内BlyS的表达水平显著高于正常对照者(P<0.01),且Ⅳ型与Ⅴ型LN肾内BlyS的表达水平均明显高于Ⅲ型LN(P<0.05),而Ⅳ型与Ⅴ型LN间BlyS的表达水平虽差异无统计学意义,但有升高趋势。结论 SLE患者血清BlyS的水平升高,LN患者肾内BlyS的表达水平升高,肾内BR3受体有极少量的表达,提示BlyS及其BR3的变化与LN的病理变化有关。 Objective To explore the role of B lymphocyte stimulator (BlyS) and BR3 in lupus nephritis (LN). Methods The serum concentrations of Blys,TNF-α and IL-1 were detected by ELISA in SLE patients and normal controls, and intrarenal expressions of BlyS and BR3 were detected by immunohistochemistry in renal tissues of LN patients and normal-appearing renal tissues. Results The serum concentrations of Bly5, TNF-α and IL-1 in SLE patients were obviously higher than those in normal controls(P 〈 0.01 ) ; Intermediate-intensity staining of BlyS was detected in renal tubules in normal-appearing renal tissues, however, both renal tubules and infiltrating cells had the ability to produce BIyS in LN patients ; All of the normal-appearing renal tissues were negative for BR3, and it was restricted to a small population of infiltrating cells in renal tissues of LN patients; The intrarenal production of BlyS in LN patients was obviously higher than that in normal-appearing renal tissues( P 〈 0.01 ), and the expression levels of BlyS in LN Ⅳ and Ⅴ were higher than those in LN Ⅳ (P 〈 0. 05 ), although there was no statistically significant difference between LN Ⅳ and V, we could see a rise trend in the expression levels of BlyS. Conclusion The serum BlyS level is significantly elevated in SLE patients. Intrarenal expression of BlyS is elevated in LN patients, and there is no significant intrarenal expression of BR3. There may exsit some association between the change of BlyS and BR3 and the diversity of the pathology category of LN.
出处 《安徽医科大学学报》 CAS 北大核心 2012年第6期659-662,共4页 Acta Universitatis Medicinalis Anhui
关键词 系统性红斑狼疮 B淋巴细胞刺激因子 BR3 systemic lupus erythmatosus B lymphocyte stimulator BR3
  • 相关文献

参考文献13

  • 1Moore P A, Belvedere O, Orr A, et al. BlyS: member of the tumor necrosis family and B lymphocyte stimulator [ J ]. Science, 1999, 285 ( 5425 ) :260 - 3.
  • 2Mackay F, Woodcock S A, Lawton P, et al. Mice transgenetic for BAFF develop lymphocytic disorders along with autoimmune mani- festations[J]. J Exp Med, 1999, 190(11) :1697 -710.
  • 3Gross J A, Johnston J, Mudri S, et al. TACI and BCMA are re- ceptors for a TNF homologue implicated in B-cell autoimmune dis- ease[J]. Nature, 2000, 404(6781 ):995-9.
  • 4徐亮,李志,张军,陆进明.血清B淋巴细胞刺激因子在系统性红斑狼疮中的意义[J].中华风湿病学杂志,2007,11(7):417-419. 被引量:4
  • 5Collins C E, Gavin A L, Miqone T S, et al. B lymphocyte stimu- lator(BlyS) isforms in systemic lupus erythematosus:disease activ- ity correlates better with blood leukocyte BlyS mRNA levels than with plasma BlyS protein levels[ J]. Arthritis Res Ther, 2006, 8 (1) :R6.
  • 6王晓燕,王永福,李青,张文兰,庞春艳.TNF-α及其可溶性受体在系统性红斑狼疮中的临床意义[J].包头医学院学报,2008,24(5):494-496. 被引量:6
  • 7Pelekanou V, Notas G, Theodoropoulou K, et al. Detection of TN- FSF members BAFF, APRIL, TWEAK and their receptors in nor- real kidney and renal cell carcinomas [ J ]. Anal Cell Pathol, 2011,34(1 -2) :49 -60.
  • 8O' Connor B P, Raman V S, Erikson L D, et al. BCMA is essen- tial for the survival of long-lived bone marrow plasma cells [ J ]. J Exp Med,2004,199 ( 1 ) : 91 - 8.
  • 9Seshasayee D, Valdez P, Yan M, et al. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an in- hibitory BlyS receptor [ J ]. Immunity, 2003,18 ( 2 ) : 279 - 88.
  • 10Sasaki Y, Casola S, Kutok J L, et al. TNF family member B-cell activating factor ( BAFF ) receptor-dependent and-independent roles for BAFF in B cell physiology [ J]. J Immunol, 2004,173 (4) :2245 -52.

二级参考文献14

  • 1Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocyte disorders along with autoimmune manifestations. J Exp Med, 1999, 190: 1697-1710.
  • 2Petri M, Stohl W, Chatham W, et al. Association of BLYS with measures of disease activity in a prospective SLE observational study. Arthritis Rheum, 2004, 50: S603.
  • 3Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1997, 40: 1725.
  • 4Stohl W, Xu D, Kim KS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum, 2005, 52: 2080-2091.
  • 5Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci, 2005, 1050: 34-39.
  • 6Moore PA, Belvedere O, Orr A, et al. BlyS:member of the the tumor necrosis factor family and B lymphocyte stimulator. Science, 1999, 285: 260-263.
  • 7Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator in systemic immune-based rheumatic diseases. Arthritis Rheum, 2001, 44: 1313-1319.
  • 8Collins CE, Gavin AL, Migone TS, et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates with blood leukocyte BlyS mRNA levels than with plasma BlyS protein levels. Arthritis Res Therapy, 2005, 7: 1186-1198.
  • 9Tan EM, Cohen AS, Fries JF,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus[ J ]. Arthrifts Rheum, 1982,25 ( 11 ) : 1271 - 1277.
  • 10Illei GG,Tackey E,Lapteva L,et al. Biomarkers in systemic lupus erythematosus: Ⅱ. Markers of disease activity[J]. Arthritis Rheum,2004,50:2048 - 2065.

共引文献8

同被引文献25

  • 1李东升,王玮蓁,孙春艳,戴明,朱林学,段逸群.系统性红斑狼疮患者B淋巴细胞刺激因子及其受体BAFF-R的表达[J].中华皮肤科杂志,2006,39(1):10-12. 被引量:13
  • 2刘才旺,倪红兵,鞠少卿.血清B淋巴细胞刺激因子与SLE关联性的初步研究[J].现代检验医学杂志,2007,22(3):40-43. 被引量:1
  • 3蒋明,朱立平,林孝义.中华风湿病[M].北京:科学出版社,2005:989-1059.
  • 4陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 5Wallance DJ,Stohl W,Furie RA,et al. A phase II, randomized, dou- ble-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus[J]. Arthritis Rheum, 2009,61(9): 1168-1178.
  • 6Ramaujam M,Bethunaickan R,Huang W,et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice[J]. Arthritis Rheum. 2010,62(5):1457- 68.
  • 7Furie R,Petri M,Zamani O,et al. A phase , randomized, placebo- controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011,12 (63) : 3918-30.
  • 8No authors listed. Guidelines for referral and management of sys- temic lupus erythematosus in adults. American College of Rheu- matology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines [J]. Arthritis Rheum, 1999, 42(9): 1785-1796.
  • 9Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-Promising or crazy? [J]. Autoimmun Rev, 2012,11(5): 321-325.
  • 10Aringer M, Feierl E, Steiner G, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death [J]. Lupus,2002, 11(2): 102-108.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部